Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis

Federal University of São Paulo33 enrolled

Overview

Ganciclovir ophthalmic gel delivers multiple advantages in the treatment and prophylaxis of herpetic keratitis and shows potential for effectiveness against other viral ocular infections. The majority of adenoviral conjunctivitis will resolve without damaging vision, however, the investigators have no way to determine which cases will progress to ocular complications such as corneal infiltrates and pseudomembranes. Our purpose is to evaluate the efficacy of the Ganciclovir gel 0.15% in preventing ocular complications after adenoviral conjunctivitis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Conjunctivitis, Viral Adenoviridae Infections

Interventions

Ganciclovir 0.15% Ophthalmic gel

Artificial tearDRUG

Artificial tear 5 times per day

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * onset of symptoms for five days or less * eighteen years old or more * not pregnant or breastfeeding * be able to understand and sign the consent term Exclusion Criteria: * use of antibiotic or corticoid 30 days before * monocular vision * keratopathy or other ocular diseases

Locations (1)

Federal University of Sao Paulo

São Paulo, São Paulo, Brazil

Outcomes

Primary Outcomes

improvement of symptoms of conjunctivitis (pain relief)

Time frame: 6 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.